SCHOTT Pharma Starts FY 2026 Strong; Outlook Confirmed

• SCHOTT Pharma started 2026 with a revenue increase of 4.8% at constant currencies to EUR 240.2 million in Q1; EBITDA margin improved to 27.1%
• The company's high-value solutions (HVS) remained a significant part of sales at 57%, maintaining the strong performance from 2025
• The Drug Containment Solutions (DCS) segment drove growth with a 9.4% revenue increase at constant currencies, and an EBITDA growth of 18.9% to EUR 33.4 million
• The Drug Delivery Systems (DDS) segment saw stable revenues of EUR 103.1 million, with demand for prefillable glass syringes remaining high, though EBITDA declined by 7.3% to EUR 32.6 million
• Operating cash flow was EUR 3.4 million, lower than the previous year due to working capital changes, but the company continued investing in capacity expansion, especially in Switzerland and Hungary with EUR 23.4 million CAPEX
• The outlook for 2026 remains positive, with revenue growth of 2–5% at constant currencies and an EBITDA margin around 27%, confirming previous forecasts

The next important date, Quarterly Report (Q1 2026), at SCHOTT Pharma is on 11.02.2026.

The price of SCHOTT Pharma at the time of the news was 14,680EUR and was up +0,07 % compared with the previous day.
17 minutes after the article was published, the price was 14,830EUR this corresponds to a plus of +1,02 % since publication.
At this time, the index SDAX was at 18.318,89PKT (+1,15 %).

SCHOTT Pharma

-2,43 %

-6,33 %

-5,29 %

-13,80 %

-46,04 %

-50,25 %

ISIN:DE000A3ENQ51WKN:A3ENQ5

• Intraday
• 5 Tage
• 1 Monat
• 3M
• 1 Jahr
• Max